Interim analysis of the ACTION trial: Cabozantinib for hepatocellular carcinoma patients who discontinued first line treatment other than sorafenib or due to sorafenib intolerance von Zamparelli, Marco Sanduzzi, Martinez, Sergio Muñoz, Calvo, Mariona, Varela, Maria, Llarch, Neus, Iserte, Gemma, Laquente, Berta, Castano-Garcia, Andrés, Lledó, José Luis, Perelló, Christie, Domenech, Gemma, Mauro, Ezequiel, García-Criado, Maria Ángeles, Ayuso, Carmen, Kateb, Angels, Rimola, Jordi, Bruix, Jordi, Reig, María

Volltext

THU-124 - Interim analysis of the ACTION trial: Cabozantinib for hepatocellular carcinoma patients who discontinued first line treatment other than sorafenib or due to sorafenib in... von Zamparelli, Marco Sanduzzi, Martinez, Sergio Muñoz, Calvo, Mariona, Varela, Maria, Llarch, Neus, Iserte, Gemma, Laquente, Berta, Castano-Garcia, Andrés, Lledó, José Luis, Perelló, Christie, Domenech, Gemma, Mauro, Ezequiel, García-Criado, Maria Ángeles, Ayuso, Carmen, Kateb, Angels, Rimola, Jordi, Bruix, Jordi, Reig, María

Volltext

Abstract 1377: Improved ctDNA detection in early stage non-small-cell lung cancer von Heider, Katrin, Wan, Jonathan C., Gale, Davina, Mouliere, Florent C., Qian, Wendi, Kateb, Angels, Doughton, Gail, Ramenatte, Nicola, Tysoe, Ruth, Smith, Christopher G., Rassl, Doris M., Harden, Susan, Rintoul, Robert C., Massie, Charles, Rosenfeld, Nitzan

Volltext